Lactoferrin benefits

Lactoferrin is among the more heavily studied proteins in food science and among the less heavily tested in large human trials. The benefits claimed for it on supplement labels and health sites far outrun the second list. This page sets the two side by side.

Each claim below has its own page, and each page states its grade before any prose. The grade comes from the best available evidence, not the most recent study and not the most favorable one. The full scale, and the ledger of every graded claim, sits on the lactoferrin overview.

Where human trials support a benefit

The strongest human case concerns iron deficiency anemia in pregnancy. A meta-analysis of four randomized trials, 600 women in all, compared oral bovine lactoferrin with ferrous iron. Hemoglobin rose slightly more on lactoferrin (mean difference 0.77 g/dL, 95% CI 0.04 to 1.55), and digestive side effects were less frequent. The lower bound of that interval barely clears zero, so the grade is Supported rather than Established. The iron deficiency anemia page sets out the subgroup detail.

The second claim rests on more pooled data than any other on this site. Two meta-analyses published in 2009 examined lactoferrin added to standard Helicobacter pylori eradication therapy. One pooled five randomized trials with 682 participants and found an odds ratio for eradication of 2.22 (95% CI 1.44 to 3.44). Its authors described the evidence as limited. The other pooled nine trials with 1,343 participants, reporting eradication in 86.6% of those given lactoferrin against 74.4% without. Randomized trials in 2021 and 2026, covering 560 more patients, found the same direction. The page on lactoferrin and H. pylori eradication tabulates all five studies and sets out why the grade stops at Supported: most of these trials were open-label, and several compared lactoferrin against no treatment rather than placebo.

Where large trials found no effect

Two claims have been tested in randomized trials sized in advance to detect the effect, and both failed.

Small trials had suggested that bovine lactoferrin prevented infection in very preterm infants. The ELFIN trial randomized 2,203 of them. Late-onset infection occurred in 316 of 1,093 infants on lactoferrin and 334 of 1,089 on placebo (adjusted risk ratio 0.95, 95% CI 0.86 to 1.04). The preterm infant page covers why that result outranks the earlier ones.

COVID-19 followed a similar path. Four randomized trials, 553 participants in total, tested lactoferrin for prevention, for hospital treatment and for long COVID. In the largest, a blinded trial of 218 hospitalized adults, the risk ratio for death or intensive care admission was 1.06 (95% CI 0.63 to 1.79). The COVID-19 page reports all four.

Where the evidence is laboratory work

Lactoferrin's antibacterial activity is well documented in culture. It binds the iron that bacteria need, and part of the molecule disrupts bacterial membranes directly. That work is sound. It is graded Laboratory only because culture conditions differ from a human gut, and because the clinical trials that followed it, in preterm infants and in COVID-19, did not find an effect. The antibacterial action page explains both mechanisms.

Where the pooled trials cannot agree

The broadest claim made for lactoferrin is also the hardest to grade. Three meta-analyses of infection outcomes have appeared since 2021, and they return different answers depending on whether adults and children are pooled together. Separated, the reduction in respiratory infection sits with infants and children, while the adult estimate is an odds ratio of exactly 1.00. The page on lactoferrin and immune support tables all six pooled estimates and grades the claim Insufficient.

Gut health reaches the same grade by a different route. The pooled analyses here agree with each other rather than conflicting: a Cochrane review found no reduction in necrotizing enterocolitis across seven trials and 4,874 preterm infants, and a 2025 review found fewer children with diarrhea across fourteen trials. Neither population is an adult buying a supplement, and the adult gut has been sequenced once, in 66 people, as a pre-specified exploratory outcome. The page on lactoferrin and gut health tables all seven measurements and grades the adult claim Insufficient.

Claims about skin have not been graded here yet, and that page will come once the primary literature behind it has been read. Where that literature turns out to be a registry entry with no published result, the grade will say so, and lactoferrin research records the trials themselves with the status each one reached.

Benefits and harms

A benefit only means something next to the harms. Supplemental lactoferrin comes from cow's milk, which rules it out for people with a milk protein allergy, and most trials are too small to detect rare adverse effects. The page on lactoferrin side effects reports what trials recorded.

Every graded claim